PACIFIC Phase III trial data at ESMO also
showed an estimated 35% of non-small cell lung cancer patients
treated with IMFINZI® had not progressed after four years
CASPIAN Phase III trial data also at ESMO
underscored long-term benefit in a proportion of patients with
extensive-stage small cell lung cancer
Updated results from the PACIFIC Phase III trial showed
AstraZeneca’s IMFINZI® (durvalumab) demonstrated a sustained,
clinically meaningful overall survival (OS) and progression-free
survival (PFS) benefit in patients with unresectable, Stage III
non-small cell lung cancer (NSCLC) who had not progressed following
concurrent chemoradiation therapy (CRT).
One in three patients with NSCLC are diagnosed at Stage III,
where the majority of tumors are unresectable (cannot be removed
with surgery).1,2 Prior to the approval of IMFINZI in this setting,
no new treatments beyond CRT had been available to these patients
for decades.3,4,5
The results from the updated post-hoc analyses showed an
estimated four-year overall survival rate of 49.6% for IMFINZI
versus 36.3% for placebo after CRT. Median OS was 47.5 months for
IMFINZI versus 29.1 for placebo. With a maximum treatment course of
one year, an estimated 35.3% of patients treated with IMFINZI had
not progressed four years after enrollment versus 19.5% for
placebo. These data build on The New England Journal of Medicine
publication from 2018 demonstrating a significant benefit for
IMFINZI in the OS primary endpoint.6
Corinne Faivre-Finn, Professor at The University of Manchester
and The Christie NHS Foundation Trust, and a lead investigator in
the PACIFIC Phase III trial, said: “Previously, only 15 to 30
percent of patients with unresectable, Stage III non-small cell
lung cancer survived five years, and the majority eventually
progressed to metastatic disease. These data show about half of
patients treated with IMFINZI survived four years, and an estimated
35 percent had not progressed, a remarkable advance in this
curative-intent setting.”
José Baselga, Executive Vice President, Oncology R&D, said:
“These unprecedented four-year results reinforce IMFINZI as the
established standard of care in unresectable, Stage III non-small
cell lung cancer and set a new survival benchmark in a setting
where cure is the treatment goal. With data also at ESMO for
CASPIAN in small cell lung cancer patients, IMFINZI continues to
deliver impressive long-term benefits across different types of
lung cancer.”
In the primary OS analysis of the PACIFIC Phase III trial, the
most common adverse events (AE) (greater than or equal to 20%)
among patients treated with IMFINZI versus placebo were cough
(35.2% versus 25.2%), fatigue (24.0% versus 20.5%), dyspnea (22.3%
versus 23.9%) and radiation pneumonitis (20.2% versus 15.8%). A
grade 3 or 4 AE was experienced by 30.5% of patients treated with
IMFINZI versus 26.1% for placebo, and 15.4% of patients
discontinued treatment due to AEs with IMFINZI versus 9.8% for
placebo.
CASPIAN Phase III Trial Exploratory Subgroup Analyses in
Extensive-Stage Small Cell Lung Cancer (ES-SCLC) at the European
Society for Medical Oncology (ESMO) Virtual Congress 2020
New exploratory subgroup analyses from the CASPIAN Phase III
trial of IMFINZI were conducted to characterize patients deriving
long-term benefit. More than three times as many patients treated
with IMFINZI plus chemotherapy were alive and progression free for
one year or more (PFS ≥12 months) versus chemotherapy alone (17%
versus 4.5%). Across all treatment arms, the subgroup of patients
who were progression free at one year had a 75% chance of being
alive at two years. In comparison, the subgroup of patients whose
disease had progressed within one year (PFS <12 months) had a
10% chance of being alive at two years. Clinical characteristics
did not appear to identify patients who derived long-term
benefit.
Patients with PFS ≥12 months received more cycles of IMFINZI
treatment compared to patients with PFS <12 months (median of 25
cycles versus 7). Although patients with greater exposure to
IMFINZI had numerically higher rates of immune-mediated AEs, the
two subgroups had similar rates of severe AEs, serious AEs and AEs
leading to discontinuation.
The CASPIAN trial met the primary endpoint of OS in 2019,
reducing the risk of death by 27% in patients with ES-SCLC treated
with IMFINZI plus a choice of chemotherapy versus chemotherapy
alone. The safety and tolerability of IMFINZI plus chemotherapy
were consistent with the known safety profiles of these medicines.
These results were published in The Lancet in 2019 and formed the
basis of regulatory approvals around the world.7
Results from the PACIFIC and CASPIAN Phase III trials were
presented during the ESMO Virtual Congress on September 19 and
September 21, 2020.
Important Safety Information
There are no contraindications for IMFINZI® (durvalumab).
IMFINZI can cause serious, potentially fatal adverse reactions
including immune-mediated pneumonitis, hepatitis, colitis,
endocrinopathies, nephritis, dermatologic reactions, other
immune-mediated adverse reactions, infection, and infusion-related
reactions. Please refer to the full Prescribing Information for
important dosage modification and management information specific
to adverse reactions.
Immune-Mediated Pneumonitis
IMFINZI can cause immune-mediated pneumonitis, defined as
requiring use of corticosteroids. Fatal cases have been reported.
Monitor patients for signs and symptoms of pneumonitis and evaluate
with radiographic imaging when suspected. Administer
corticosteroids for Grade 2 or greater pneumonitis. Withhold
IMFINZI for Grade 2 pneumonitis; permanently discontinue for Grade
3 or 4 pneumonitis.
In clinical studies enrolling 1889 patients with various cancers
who received IMFINZI, pneumonitis occurred in 5% of patients,
including Grade 3 (0.8%), Grade 4 (<0.1%), and Grade 5 (0.3%)
pneumonitis. Pneumonitis led to discontinuation of IMFINZI in 1.5%
of the 1889 patients. The incidence of pneumonitis (including
radiation pneumonitis) was higher in patients in the PACIFIC study
who completed treatment with definitive chemoradiation within 42
days prior to initiation of IMFINZI (34%) compared to patients in
other clinical studies (2.3%) in which radiation therapy was
generally not administered immediately prior to initiation of
IMFINZI. In the PACIFIC study, the incidence of Grade 3 pneumonitis
was 3.4% and of Grade 5 pneumonitis was 1.1% in the IMFINZI arm. In
the PACIFIC study, pneumonitis led to discontinuation of IMFINZI in
6% of patients.
The frequency and severity of immune-mediated pneumonitis were
similar whether IMFINZI was given as a single agent in patients
with various cancers or in combination with chemotherapy in
patients with ES-SCLC.
Immune-Mediated Hepatitis
IMFINZI can cause immune-mediated hepatitis, defined as
requiring use of corticosteroids. Fatal cases have been reported.
Monitor patients for signs and symptoms of hepatitis during and
after discontinuation of IMFINZI, including clinical chemistry
monitoring. Administer corticosteroids for Grade 2 or higher
elevations of ALT, AST, and/or total bilirubin. Withhold IMFINZI
for ALT or AST greater than 3 but less than or equal to 8 times the
ULN or total bilirubin greater than 1.5 but less than or equal to 5
times the ULN; permanently discontinue IMFINZI for ALT or AST
greater than 8 times the ULN or total bilirubin greater than 5
times the ULN or concurrent ALT or AST greater than 3 times the ULN
and total bilirubin greater than 2 times the ULN with no other
cause.
In clinical studies enrolling 1889 patients with various cancers
who received IMFINZI, hepatitis occurred in 12% of patients,
including Grade 3 (4.4%), Grade 4 (0.4%), and Grade 5 (0.2%)
hepatitis. Hepatitis led to discontinuation of IMFINZI in 0.7% of
the 1889 patients.
Immune-Mediated Colitis
IMFINZI can cause immune-mediated colitis, defined as requiring
use of corticosteroids. Administer corticosteroids for Grade 2 or
greater colitis or diarrhea. Withhold IMFINZI for Grade 2 colitis
or diarrhea; permanently discontinue for Grade 3 or 4 colitis or
diarrhea.
In clinical studies enrolling 1889 patients with various cancers
who received IMFINZI, colitis or diarrhea occurred in 18% of
patients, including Grade 3 (1.0%) and Grade 4 (0.1%)
immune-mediated colitis. Diarrhea or colitis led to discontinuation
of IMFINZI in 0.4% of the 1889 patients.
Immune-Mediated Endocrinopathies
IMFINZI can cause immune-mediated endocrinopathies, including
thyroid disorders, adrenal insufficiency, type 1 diabetes mellitus,
and hypophysitis/hypopituitarism. Monitor patients for clinical
signs and symptoms of endocrinopathies.
- Thyroid disorders—Monitor thyroid function prior to and
periodically during treatment. Initiate hormone replacement therapy
or medical management of hyperthyroidism as clinically indicated.
Withhold IMFINZI for Grades 2–4 hyperthyroidism, until clinically
stable. Continue IMFINZI for hypothyroidism. In clinical studies
enrolling 1889 patients with various cancers who received IMFINZI,
hypothyroidism occurred in 11% of patients, while hyperthyroidism
occurred in 7% of patients. Thyroiditis occurred in 0.9% of
patients, including Grade 3 (<0.1%) thyroiditis. Hypothyroidism
was preceded by thyroiditis or hyperthyroidism in 25% of
patients.
- Adrenal insufficiency—Administer corticosteroids as
clinically indicated and withhold IMFINZI until clinically stable
for Grade 2 or higher adrenal insufficiency. In clinical studies
enrolling 1889 patients with various cancers who received IMFINZI,
adrenal insufficiency occurred in 0.7% of patients, including Grade
3 (<0.1%) adrenal insufficiency.
- Type 1 diabetes mellitus—Initiate treatment with insulin
as clinically indicated. Withhold IMFINZI for Grades 2–4 type 1
diabetes mellitus, until clinically stable. In clinical studies
enrolling 1889 patients with various cancers who received IMFINZI,
type 1 diabetes mellitus occurred in <0.1% of patients.
- Hypophysitis—Administer corticosteroids and hormone
replacement as clinically indicated and withhold IMFINZI until
clinically stable for Grade 2 or higher hypophysitis.
Hypopituitarism leading to adrenal insufficiency and diabetes
insipidus occurred in <0.1% of 1889 patients with various
cancers who received IMFINZI.
Immune-Mediated Nephritis
IMFINZI can cause immune-mediated nephritis, defined as evidence
of renal dysfunction requiring use of corticosteroids. Fatal cases
have occurred. Monitor patients for abnormal renal function tests
prior to and periodically during treatment with IMFINZI. Administer
corticosteroids as clinically indicated. Withhold IMFINZI for
creatinine greater than 1.5 to 3 times the ULN; permanently
discontinue IMFINZI and administer corticosteroids in patients with
creatinine greater than 3 times the ULN.
In clinical studies enrolling 1889 patients with various cancers
who received IMFINZI, nephritis (reported as any of the following:
increased creatinine or urea, acute kidney injury, renal failure,
decreased glomerular filtration rate, tubulointerstitial nephritis,
decreased creatinine clearance, glomerulonephritis, and nephritis)
occurred in 6.3% of the patients including Grade 3 (1.1%), Grade 4
(0.2%), and Grade 5 (0.1%) nephritis. IMFINZI was discontinued in
0.3% of the 1889 patients.
Immune-Mediated Dermatologic Reactions
IMFINZI can cause immune-mediated rash. Stevens Johnson Syndrome
(SJS)/toxic epidermal necrolysis (TEN) has occurred with other
products in this class. Administer corticosteroids for Grade 2 rash
or dermatitis lasting for more than 1 week or for Grade 3 or 4 rash
or dermatitis. Withhold IMFINZI for Grade 2 rash or dermatitis
lasting longer than 1 week or Grade 3 rash or dermatitis;
permanently discontinue IMFINZI in patients with Grade 4 rash or
dermatitis.
In clinical studies enrolling 1889 patients with various cancers
who received IMFINZI, 26% of patients developed rash or dermatitis
and 0.4% of the patients developed vitiligo. Rash or dermatitis led
to discontinuation of IMFINZI in 0.1% of the 1889 patients.
Other Immune-Mediated Adverse Reactions
IMFINZI can cause severe and fatal immune-mediated adverse
reactions. These immune-mediated reactions may involve any organ
system. While immune-mediated reactions usually manifest during
treatment with IMFINZI, immune-mediated adverse reactions can also
manifest after discontinuation of IMFINZI. For suspected
immune-mediated adverse reactions, exclude other causes and
initiate corticosteroids as clinically indicated. Withhold IMFINZI
for Grade 3 immune-mediated adverse reactions, unless clinical
judgment indicates discontinuation; permanently discontinue IMFINZI
for Grade 4 adverse reactions.
The following clinically significant, immune-mediated adverse
reactions occurred at an incidence of less than 1% each in 1889
patients who received IMFINZI: aseptic meningitis, hemolytic
anemia, immune thrombocytopenic purpura, myocarditis, myositis, and
ocular inflammatory toxicity, including uveitis and keratitis. In
patients who received IMFINZI in clinical studies outside of the
pooled dataset, myasthenia gravis occurred at an incidence of less
than 0.1%. Permanently discontinue IMFINZI if myasthenia gravis
does not resolve to ≤ Grade 1 within 30 days or if there are signs
of respiratory and/or autonomic insufficiency. Additional
clinically significant immune-mediated adverse reactions have been
seen with other products in this class (see Warnings and
Precautions Section 5.7 of IMFINZI full Prescribing
Information).
Infection
IMFINZI can cause serious infections, including fatal cases.
Monitor patients for signs and symptoms of infection and treat as
clinically indicated. Withhold IMFINZI for Grade 3 or 4 infection,
until clinically stable.
In clinical studies enrolling 1889 patients with various cancers
who received IMFINZI, infections occurred in 43% of patients,
including Grade 3 (8%), Grade 4 (1.9%), and Grade 5 (1.0%). The
overall incidence of infections in IMFINZI-treated patients in the
PACIFIC study (56%) was higher compared to patients in other
clinical studies (38%) in which radiation therapy was generally not
administered immediately prior to initiation of IMFINZI. In
patients with UC in Study 1108 (n=182), the most common Grade 3 or
higher infection was urinary tract infections, which occurred in 4%
of patients. In patients with Stage III NSCLC in the PACIFIC study,
the most common Grade 3 or higher infection was pneumonia, which
occurred in 5% of patients.
Infusion-Related Reactions
IMFINZI can cause severe or life-threatening infusion-related
reactions. Monitor patients for signs and symptoms of an
infusion-related reaction. Interrupt or slow the rate of infusion
for Grades 1–2 infusion-related reactions; permanently discontinue
for Grades 3–4 infusion-related reactions.
In clinical studies enrolling 1889 patients with various cancers
who received IMFINZI, infusion-related reactions occurred in 2.2%
of patients, including Grade 3 (0.3%).
Embryo-Fetal Toxicity
Based on its mechanism of action and data from animal studies,
IMFINZI can cause fetal harm when administered to a pregnant woman.
There are no data on the use of IMFINZI in pregnant women. Advise
pregnant women of the potential risk to a fetus and advise women of
reproductive potential to use effective contraception during
treatment and for at least 3 months after the last dose of
IMFINZI.
Lactation
There is no information regarding the presence of IMFINZI in
human milk; however, because of the potential for adverse reactions
in breastfed infants from IMFINZI, advise women not to breastfeed
during treatment and for at least 3 months after the last dose.
Most Common Adverse Reactions
- In patients with UC in Study 1108 (n=182), the most common
adverse reactions (≥15%) were fatigue (39%), musculoskeletal pain
(24%), constipation (21%), decreased appetite (19%), nausea (16%),
peripheral edema (15%), and urinary tract infection (15%). The most
common Grade 3 or 4 adverse reactions (≥3%) were fatigue, urinary
tract infection, musculoskeletal pain, abdominal pain, dehydration,
and general physical health deterioration
- In patients with UC in Study 1108, discontinuation due to
adverse reactions occurred in 3.3% of patients. Serious adverse
reactions occurred in 46% of patients. The most frequent serious
adverse reactions (>2%) were acute kidney injury (4.9%), urinary
tract infection (4.4%), musculoskeletal pain (4.4%), liver injury
(3.3%), general physical health deterioration (3.3%), sepsis,
abdominal pain, and pyrexia/tumor associated fever (2.7% each)
- In patients with Stage III NSCLC in the PACIFIC study (IMFINZI
n=475), the most common adverse reactions (≥20% of patients) were
cough (40%), fatigue (34%), pneumonitis or radiation pneumonitis
(34%), upper respiratory tract infections (26%), dyspnea (25%), and
rash (23%). The most common Grade 3 or 4 adverse reactions (≥3%)
were pneumonitis/radiation pneumonitis (3.4%) and pneumonia
(7%)
- In patients with Stage III NSCLC in the PACIFIC study (IMFINZI
n=475), discontinuation due to adverse reactions occurred in 15% of
patients in the IMFINZI arm. Serious adverse reactions occurred in
29% of patients receiving IMFINZI. The most frequent serious
adverse reactions (≥2% of patients) were pneumonitis or radiation
pneumonitis (7%) and pneumonia (6%). Fatal pneumonitis or radiation
pneumonitis and fatal pneumonia occurred in <2% of patients and
were similar across arms
- In patients with extensive-stage SCLC in the CASPIAN study
(n=265), the most common adverse reactions (≥20%) were nausea,
fatigue/asthenia, and alopecia. The most common Grade 3 or 4
adverse reaction (≥3%) was fatigue/asthenia (3.4%)
- In patients with extensive-stage SCLC in the CASPIAN study
(n=265), IMFINZI was discontinued due to adverse reactions in 7% of
the patients receiving IMFINZI plus chemotherapy. Serious adverse
reactions occurred in 31% of patients receiving IMFINZI plus
chemotherapy. The most frequent serious adverse reactions reported
in at least 1% of patients were febrile neutropenia (4.5%),
pneumonia (2.3%), anemia (1.9%), pancytopenia (1.5%), pneumonitis
(1.1%), and COPD (1.1%). Fatal adverse reactions occurred in 4.9%
of patients receiving IMFINZI plus chemotherapy
The safety and effectiveness of IMFINZI have not been
established in pediatric patients.
Indications
IMFINZI is indicated for the treatment of adult patients with
locally advanced or metastatic urothelial carcinoma who:
- Have disease progression during or following
platinum-containing chemotherapy.
- Have disease progression within 12 months of neoadjuvant or
adjuvant treatment with platinum-containing chemotherapy.
This indication is approved under accelerated approval based on
tumor response rate and duration of response. Continued approval
for this indication may be contingent upon verification and
description of clinical benefit in confirmatory trials.
IMFINZI is indicated for the treatment of adult patients with
unresectable Stage III non-small cell lung cancer (NSCLC) whose
disease has not progressed following concurrent platinum-based
chemotherapy and radiation therapy.
IMFINZI, in combination with etoposide and either carboplatin or
cisplatin, is indicated for the first-line treatment of adult
patients with extensive-stage small cell lung cancer (ES-SCLC).
Please see complete Prescribing Information, including
Medication Guide.
NOTES TO EDITORS
About Lung cancer
Lung cancer is the leading cause of cancer death among both men
and women and accounts for about one fifth of all cancer deaths.8
Lung cancer is broadly split into NSCLC and SCLC, with about 85%
classified as NSCLC and 15% classified as SCLC.9
Stage III NSCLC (locally advanced) is commonly divided into
three sub-categories (IIIA, IIIB and IIIC), defined by how much the
cancer has spread locally and the possibility of surgery.10 Stage
III disease is different from Stage IV disease, when the cancer has
spread (metastasized), as the majority of Stage III patients are
treated with curative intent.10,11 In 2015, Stage III NSCLC was
estimated to affect nearly 200,000 patients in the following eight
key countries: China, France, Germany, Italy, Japan, Spain, UK, and
the US, with approximately 43,000 cases in the US alone.2
SCLC is a highly aggressive, fast-growing form of lung cancer
that typically recurs and progresses rapidly, despite initial
response to chemotherapy.12,13 About two thirds of SCLC patients
are diagnosed with extensive-stage disease, in which the cancer has
spread widely through the lung or to other parts of the body.14
Prognosis is particularly poor, as only 6% of all SCLC patients
will be alive five years after diagnosis.14
About PACIFIC
The PACIFIC trial was a Phase III, randomized, double-blinded,
placebo-controlled, multi-center trial of IMFINZI (durvalumab) as
treatment in “all-comer’” patients (regardless of PD-L1 status)
with unresectable, Stage III NSCLC whose disease had not progressed
following concurrent platinum-based CRT.
The trial was conducted at 235 centers across 26 countries
involving 713 patients. The primary endpoints of the trial were PFS
and OS, and secondary endpoints included landmark PFS and OS,
objective response rate (ORR) and duration of response (DoR).
About CASPIAN
CASPIAN is a randomized, open-label, multi-center, global, Phase
III trial in the 1st-line treatment of 805 patients with ES-SCLC.
The trial compared IMFINZI in combination with etoposide and either
carboplatin or cisplatin chemotherapy, or IMFINZI and chemotherapy
with the addition of a second immunotherapy, tremelimumab, versus
chemotherapy alone. In the experimental arms, patients were treated
with up to four cycles of chemotherapy. In comparison, the control
arm allowed up to six cycles of chemotherapy and optional
prophylactic cranial irradiation. The trial is being conducted in
more than 200 centers across 23 countries, including the US, in
Europe, South America, Asia and the Middle East. The primary
endpoint is OS in each of the experimental arms.
About IMFINZI® (durvalumab)
IMFINZI is a human monoclonal antibody that binds to PD-L1 and
blocks the interaction of PD-L1 with PD-1 and CD80, countering the
tumor’s immune-evading tactics and releasing the inhibition of
immune responses.
IMFINZI is approved in the curative-intent setting of
unresectable, Stage III NSCLC after chemoradiation therapy in the
US, Japan, China, across the EU and in many other countries, based
on the Phase III PACIFIC trial. IMFINZI is approved for the
1st-line treatment of ES-SCLC in combination with standard of care
(SoC) chemotherapy in the US and Singapore. IMFINZI is also
approved for previously treated patients with advanced bladder
cancer in the US and a small number of other countries.
As part of a broad development program, IMFINZI is also being
tested as a monotherapy and in combination with tremelimumab, an
anti-CTLA4 monoclonal antibody and potential new medicine, as a
treatment for patients with NSCLC, SCLC, bladder cancer, head and
neck cancer, liver cancer, biliary tract cancer, cervical cancer
and other solid tumors.
About AstraZeneca Support Programs
AstraZeneca strives to ensure that appropriate patients and
their oncologists have access to IMFINZI and relevant support
resources. These include educational resources, an Oncology Nurse
Educator program and affordability and reimbursement programs, such
as Access 360™.
Additionally, AstraZeneca has launched Lighthouse, a program
that provides support to patients during any immune-mediated
adverse events they may encounter during treatment, through
medically trained Lighthouse Advocates. The program aims to make
patients’ treatment experience as comfortable as possible. Find out
more about Lighthouse at LighthouseProgram.com or call
1-855-LHOUSE1(1-855-546-8731).
About AstraZeneca in lung cancer
AstraZeneca has a comprehensive portfolio of approved and
potential new medicines in late-stage development for the treatment
of different forms of lung cancer spanning different histologies,
several stages of disease, lines of therapy and modes of
action.
An extensive Immuno-Oncology development program focuses on lung
cancer patients without a targetable genetic mutation which
represent up to three-quarters of all patients with lung cancer.15
IMFINZI, an anti-PDL1 antibody, is in development for patients with
advanced disease (POSEIDON and PEARL Phase III trials) and for
patients in earlier stages of disease including potentially
curative settings (MERMAID-1, AEGEAN, ADJUVANT BR.31, PACIFIC-2,
PACIFIC-4, PACIFIC-5, and ADRIATIC Phase III trials) both as
monotherapy and in combination with tremelimumab and/or
chemotherapy.
About AstraZeneca’s approach to Immuno-Oncology (IO)
Immuno-oncology (IO) is a therapeutic approach designed to
stimulate the body’s immune system to attack tumors. Our IO
portfolio is anchored by immunotherapies that have been designed to
overcome anti-tumor immune suppression. We are invested in using IO
approaches that deliver long-term survival for new groups of
patients across tumor types.
We are pursuing a comprehensive clinical-trial program that
includes IMFINZI as a monotherapy and in combination with
tremelimumab in multiple tumor types, stages of disease, and lines
of therapy, and where relevant using the PD-L1 biomarker as a
decision-making tool to define the best potential treatment path
for a patient. In addition, the ability to combine the IO portfolio
with radiation, chemotherapy, small targeted molecules from across
AstraZeneca’s Oncology pipeline, and from research partners, may
provide new treatment options across a broad range of tumors.
About AstraZeneca in Oncology
AstraZeneca has a deep-rooted heritage in oncology and offers a
quickly growing portfolio of new medicines that has the potential
to transform patients' lives and the Company's future. With six new
medicines launched between 2014 and 2020, and a broad pipeline of
small molecules and biologics in development, we are committed to
advancing oncology as a key growth driver for AstraZeneca focused
on lung, ovarian, breast and blood cancers. In addition to
AstraZeneca's main capabilities, we are actively pursuing
innovative partnerships and investments that accelerate the
delivery of our strategy, as illustrated by the investment in
Acerta Pharma in hematology.
By harnessing the power of four scientific platforms –
Immuno-Oncology, Tumor Drivers and Resistance, DNA Damage Response
and Antibody Drug Conjugates – and by championing the development
of personalized combinations, AstraZeneca has the vision to
redefine cancer treatment and, one day, eliminate cancer as a cause
of death.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialization of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal &
Metabolism and Respiratory & Immunology. AstraZeneca operates
in over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information, please visit
www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.
1. Antonia SJ, et al. PACIFIC Investigators. Durvalumab After
Chemoradiotherapy In Stage III Non-Small-Cell Lung Cancer. N Engl J
Med. 2017;377(20):1919-1929. 2. Kantar Health CancerMPact.
Treatment Modality. http://cancermpact.khapps.com. Accessed
September 2020. 3. Curran WJ, et al. Sequential vs Concurrent
Chemoradiation for Stage III Non–Small Cell Lung Cancer: Randomized
Phase III Trial RTOG 9410. J Natl Cancer Inst.
2011;103(19):1452–1460. 4. NCCN Clinical Practice Guidelines in
Oncology. Non-small cell lung cancer, version 8. 2017 Aug 3. 5.
Hanna N, et al. Current Standards and Clinical Trials in Systemic
Therapy for Stage III Lung Cancer: What is New? Am Soc Clin Oncol
Educ Book. 2015;e442-447. 6. Antonia SJ, et al. Overall Survival
with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl
J Med. 2018;379(24):2342-2350. 7. Paz-Ares, et al. Durvalumab Plus
Platinum-Etoposide Versus Platinum-Etoposide in First-Line
Treatment of Extensive-Stage Small Cell Lung Cancer (CASPIAN): A
Randomized, Controlled, Open-Label, Phase 3 Trial. The Lancet.
2019;394(10,212):1929-1939. 8. American Cancer Society. Key
Statistics for Lung Cancer. Available at
https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html.
Accessed September 2020. 9. American Cancer Society. What is Lung
Cancer? Available at
https://www.cancer.org/cancer/lung-cancer/about/what-is.html.
Accessed September 2020. 10. ASCO. Cancer.net. Lung Cancer –
Non-Small Cell. Available at:
https://www.cancer.net/cancer-types/lung-cancer/view-all. Accessed
September 2020. 11. Cheema PK, et al. Perspectives on Treatment
Advances For Stage III Locally Advanced Unresectable Non-Small-Cell
Lung Cancer. Curr Oncol. 2019;26(1):37-42. 12. Kalemkerian GP, et
al. Treatment Options for Relapsed Small-Cell Lung Cancer: What
Progress Have We Made? J Oncol Pract. 2018;14(6):369-370. 13.
National Cancer Institute. NCI Dictionary – Small Cell Lung Cancer.
Available at
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/small-cell-lung-cancer.
Accessed September 2020. 14. Cancer.Net. Lung Cancer - Small Cell.
Available at https://www.cancer.net/cancer-types/33776/view-all.
Accessed September 2020. 15. Pakkala, S, et al. Personalized
therapy for lung cancer: striking a moving target. JCI Insight.
2018;3(15):e120858.
US-43737 Last Updated 9/20
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200918005086/en/
Media Inquiries Michele Meixell +1 302 885 2677
Brendan McEvoy +1 302 885 2677
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024